Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review by Tong-shuo Zhang et al.
Zhang et al. SpringerPlus  (2015) 4:776 
DOI 10.1186/s40064-015-1542-1
RESEARCH
Global publication trends and research 
hotspots of nonalcoholic fatty liver disease:  
a bibliometric analysis and systematic review
Tong‑shuo Zhang, Hua‑lei Qin, Tong Wang, Hai‑tao Li, Hai Li, Shi‑hai Xia* and Xiao‑hui Xiang*
Abstract 
With the globally increasing prevalence, nonalcoholic fatty liver disease (NAFLD) becomes the predominant cause of 
chronic liver disease. A global look at the publication trends and the research hotspots of NAFLD are urgently needed 
to assess the situation of NAFLD research. The global scientific research in the Science Citation Index‑Expanded cov‑
ered articles relevant to NAFLD was retrieved and its bibliometric parameters and research hotspots of NAFLD were 
systematically evaluated. To sum up, 6356 articles were published in 994 different journals covering 93 SCI subject cat‑
egories during 1986–2013, in which English was the most predominant language used. Starting from the late 1980s, 
the publication on NAFLD grew slowly and entered into a highly developing period in the 21st century, especially 
in the last decade. Besides hepatic steatosis, metabolic syndrome and its combination of symptoms such as obesity, 
insulin resistance are listed as the top frequent keywords. Bibliometric results suggest that the obviously rapid growth 
of the articles in recent years appears to be associated with the accelerating incidence of NAFLD and its cofactors 
such as metabolic syndrome. In addition, epidemiology focusing on comparing different regions and population is 
attracting ever‑growing attention. Meantime, pathology plays an important role in NAFLD research.
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Background
Non-alcoholic fatty liver disease (NAFLD) is a condition 
with excessive fat accumulation in the liver in individuals 
who consume little or no alcohol (van der Poorten et al. 
2008). In addition to excessive fat, the NAFLD with liver 
cell injury and inflammation, defined as non-alcoholic 
steatohepatitis (NASH), which is virtually indistinguish-
able histologically from alcoholic steatohepatitis (Cohen 
et al. 2011; LaBrecque et al. 2014). About 30 % of NAFLD 
progress to NASH, which can lead to fibrosis, cirrhosis, 
liver failure or even hepatocellular carcinoma (Chalas-
ani et al. 2012). With the globally increasing prevalence, 
NAFLD becomes the predominant cause of chronic liver 
disease in many parts of the world (Loomba and Sanyal 
2013). With the ever increasing demand for preventing or 
reversing NAFLD, it is time to have a global look at the 
history and current situation of NAFLD research.
Bibliometrics, as a main branch of information man-
agement field, utilizes quantitative analysis and statis-
tics to describe patterns of publications within a given 
topic, field, institute, or country (Han and Ho 2011). 
Bibliometric method has already been applied to medi-
cal related topics such as cancer molecular epidemiology 
(Ugolini et  al. 2007), tuberculosis (Ramos et  al. 2008), 
Alzheimer’s disease (Sorensen 2009), acupuncture (Han 
and Ho 2011), and liver diseases (Qi et  al. 2014). As an 
effective tool for measuring scientific performance as 
well as making tracks for global trends, Science Cita-
tion Index-Expanded (SCI-Expanded) from the Institute 
for Scientific Information (ISI), is the most frequently 
used source database for a broad review of scientific 
accomplishments in a specific field. This study analyzed 
the languages, subject categories, journals, countries/
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territories and institutes of articles related to NAFLD in 
SCI-Expanded from 1986 to 2013 to assess the publica-
tion trends and research hotspots in this field using a bib-
liometric method.
Method
The data were retrieved from the online version of SCI-
Expanded, Web of Science, which indexed 8618 major 
journals with citation references across 176 scientific 
disciplines in the year 2014. “Non alcoholic steatohepa-
titis”, “non alcoholic fatty liver disease” and their hetero-
morphic form as well as their abbreviation limited in liver 
or hepatology fields were used as keywords to search 
titles, abstracts, and keywords from 1986 to 2013. All 
the retrieved results were imported into Excel 2007 for 
further analysis. The impact factor (IF) of each journal 
was referred to the JCR in 2013. Contributions of differ-
ent institutes and countries/territories were estimated 
by the affiliation of the articles with at least one author. 
Addresses of the authors determined the collaboration 
type. All the articles within the past 28 years (1986–2013) 
were assessed by the following aspects: document type 
and language of articles; distribution of journals and 
subject categories; publication productions of article 
countries/territories and institutes with five indicators 
including total publications, single-country publications, 
internationally collaborative publications, first author 
articles, and corresponding author articles. Furthermore, 
the top ten frequently cited articles about NAFLD in SCI-
Expanded database were also discussed.
Some of the keywords such as “NAFLD”, “NASH” and 
“fatty liver” were discarded for the reason that they com-
pletely overlap with the research content. At the same 
time, some key words with the same meanings were uni-
fied into one since non-standardized format of key words 
might bring about statistic bias. For instance, “diabetes 
mellitus” and “diabetes” were pooled in one keyword, so 
were “hepatic fibrosis” and “liver fibrosis”.
Results
The distribution of publication type and language
There were 11,751 publications with 13 document types 
indexed in the SCI-Expanded from 1986 to 2013, which 
included 6356 articles. The original article, as the most 
popular document type, comprised 54.1  % of the total 
publications followed by meeting abstracts (2859; 24.3 %), 
reviews (1289; 11 %), letters (485; 4.1 %), editorial materials 
(440; 3.7 %), proceedings papers (250; 2.1 %). The remain-
der having less significance were corrections (36), book 
reviews (20), news items (9), book articles (4), reprints (1), 
notes (1) and addition correction (1). Only articles were 
included for further analysis, in which 14 languages were 
used. English was the most used language (6216; 97.80 %), 
and other languages frequently used were French (40; 
0.63  %), Spanish (39; 0.61  %) and German (31; 0.49  %). 
Other languages such as Russian, Portuguese, Polish, Turk-
ish only account for 0.47 % of the total articles.
Increase pattern of the article amount
After being screened, the meaningful research articles 
about NAFLD appeared in 1986. The articles in this field 
kept a very small scale during the period of 1986 to 1998. 
From 1998 to 2004, the total amount of NAFLD articles 
experienced a slowly increase. From 2004 to 2013, the 
total amount of articles in this field entered a period of 
rapid growth (Fig.  1). According to the growth trend, 
a power functional equation can be fitted as follows: 
Y = 99.279X − 198812, R2 = 0.9945.
Subject categories and journals
According to the JCR in 2013, the article output of 
NAFLD were distributed in 93 SCI subject categories. 
The top ten main subject categories were Gastroenter-
ology & Hepatology (2655, 41.8  %), Endocrinology & 
Metabolism (696, 11.0  %), Biochemistry & Molecular 
Biology (427, 6.7  %), Nutrition & Dietetics (416, 6.5  %), 
Pharmacology & Pharmacy (352, 5.5  %), Research & 
Experimental Medicine (329, 5.2 %), General & Internal 
Medicine (323, 5.1 %), Surgery (277, 4.4 %), Cell Biology 
(201, 3.2 %), and Pathology (201, 3.2 %).
Totally, 6356 articles were published in 994 journals 
including professional journals and journals of other dis-
ciplines. Among the 994 journals, 428 (43  %) journals 
only published one article and 166 (17 %) journals pub-
lished two articles so far. Thirty percent of articles were 
published in 13 core journals (Table 1). The most produc-
tive journal was Hepatology (356), followed by Journal 
of Hepatology (261), Plos One (167), World Journal of 
Gastroenterology (163), Journal of Gastroenterology and 
Hepatology (151), and Liver International (132).
Publication trends of countries/territories
Top 11 countries/territories have published over 200 arti-
cles, which were ranked in accordance with the number of 
total articles and other five indicators (Table 2). The most 
productive country was the USA (1995, 25.61 %), followed 
by Japan (802, 10.30  %), Italy (663, 8.51  %), and China 
(mainland) (549, 7.05 %). The USA had the most numer-
ous partners with 23.43 % of the internationally collabora-
tive articles, followed by Italy with 9.09 %. In addition, the 
USA ranked the top for its dominant first author articles 
(26.15 %) and corresponding author articles (26.47 %). The 
UK (56.17 %) had a relatively high percentage of interna-
tionally collaborative articles, while Germany (53.07  %) 
and Australia (52.91 %) were sequenced behind. The time 
series analysis among the top seven countries/territories 
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with more than 300 articles is shown in Fig. 2. The num-
ber of articles of the USA and China had a sharp increase 
in recent years. It is worth mentioning that China (main-
land) topped Italy in 2010, and then, leapt over Japan in 
2012 to be the second place. Moreover, some East Asian 
countries/territories occupied an important place in the 
research of NAFLD such as Japan, China (mainland), 
South Korea and Taiwan.
Publication trends of institutes
With 95 publications, University Calif San Diego 
(USA) ranked the first place, which accounted for 
Fig. 1 Number of global SCI articles varies with time. Fitting equation during 2004–2013 is: Y = 99.279X − 198812, R2 = 0.9945. In the equation, Y 
is the number of accumulation articles and X is the sequence number of the year. It indicated that research on NAFLD developed rapidly in recent 
10 years
Table 1 The 13 most productive journals with the number of articles, IF, SCI categorie of journals, and the position of the 
journal in its category
TP total publications, IF impact factor
Journal TP (%) IF SCI subject category Position
Hepatology 356 (5.60) 11.190 Gastroenterology & Hepatology 3/75
Journal of Hepatology 261 (4.10) 10.401 Gastroenterology & Hepatology 5/75
Plos One 167 (2.63) 3.534 Multidisciplinary sciences 8/55
World Journal of Gastroenterology 163 (2.56) 2.433 Gastroenterology & Hepatology 36/75
Journal of Gastroenterology and Hepatology 151 (2.38) 3.627 Gastroenterology & Hepatology 19/75
Liver International 132 (2.08) 4.447 Gastroenterology & Hepatology 14/75
Digestive Diseases and Sciences 129 (2.03) 2.55 Gastroenterology & Hepatology 32/75
Gastroenterology 108 (1.70) 13.926 Gastroenterology & Hepatology 1/75
Hepatology Research 99 (1.56) 2.218 Gastroenterology & Hepatology 41/75
American Journal Of Gastroenterology 95 (1.49) 9.213 Gastroenterology & Hepatology 6/75
Obesity Surgery 84 (1.32) 3.739 Surgery 15/204
European Journal of Gastroenterology & Hepatology 76 (1.20) 2.152 Gastroenterology & Hepatology 48/75
American Journal of Physiology‑Gastrointestinal and Liver Physiology 76 (1.20) 3.737 Gastroenterology & Hepatology 17/75
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1.51  % of the number of total articles retrieved in 
NAFLD research. Among the top 10 institutions, 7 of 
them were derived from USA, publishing 727 articles 
in total, which accounted for 11.58  % of the number 
of total articles retrieved. This indicated that the num-
ber of articles published presented a centralized trend 
as in Table 3. Overall, 6356 articles were completed by 
4136 institutions, each of which published 1.5 papers 
on average. Out of the articles, 2326 (36.60  %) arti-
cles were completed by single institutions and 3952 
(62.18  %) through inter-institutional cooperation. 
Therefore, cooperation was becoming an inevitable 
trend in NAFLD research.
The most frequent cited articles
Generally, citation frequency of articles could reflect the 
foci and the trends of research in a specific area. Anal-
ysis of the top 10 most frequently cited articles showed 
that they were respectively from USA (5 articles), Italy (4 
articles) and Australia (1 articles) (Table 4). Four articles 
were related to epidemiological studies of NAFLD, which 
were published respectively in the year of 1990 (cited 813 
times), 1999 (cited 731 times), 2004 (cited 1029 times), 
and 2005 (cited 776 times). These articles investigated the 
similarities and differences in different regions and races, 
in which the potential role of genetics, the risk factors, 
and independent predictors of NAFLD were explored. 
Another three articles were related to the relationship 
between NAFLD and metabolic syndrome, in which obe-
sity and insulin resistance were repeatedly mentioned. 
In addition, the remain three articles gave an analysis of 
NAFLD in the clinical and histological aspect. Two out of 
three articles explored the histological grading and stag-
ing of NAFLD.
The research hotspots of NAFLD
Statistically, 7011 keywords appeared 17,959 times and 
5281 keywords appeared only once. Table 5 shows the top 
11 keywords with a frequency of at least 100 times. Not all 
of the articles were included in this analysis because 1978 
(31  %) articles were short of keywords. The analysis of 
the keywords frequency related to NAFLD indicated that 
metabolic syndrome (MS) and its combination of symp-
toms (obesity, insulin resistance, oxidative stress, adiponec-
tin, and type 2 diabetes, etc.) were involved in 2029 (11 %) 
times. Among the frequency of MS related keywords, 579 
(2.9 %) times were associated with obesity and 488 (2.4 %) 
times with insulin resistance (IR). Other topics discussed 
were histological characteristics and progression of NAFLD 
(1344, 8 %). Furthermore, a similar result was shown in the 
analysis of the 10 most frequently cited articles.
Discussion
In this article, bibliometrics was used to quantitatively 
analyze global publication trends and research hotspots 
of NAFLD. The publication amount, to a certain extent, 
can reflect the development level in NAFLD research 
field.
Development of NAFLD‑related publications
Increased amount of published articles about NAFLD 
reflects the trend of the disease. NAFLD has been 
increasing worldwide over recent decades in line with 
the increased prevalence of obesity, diabetes, and hyper-
lipemia (Neuschwander-Tetri 2005). This indicates that 
research on NAFLD would develop more rapidly in 
the near future because modern sedentary and over-
nutrition lifestyle puts a very large population at risk of 
NAFLD (Farrell et al. 2013).
Table 2 Research publication trends of country/territories
TP the number of total publications, TPR (%) the rank and percentage of total publications, SPR (%) the rank and percentage of single-country publications, CPR (%) 
internationally collaborative publications, FAR (%) first author articles; RPR (%) corresponding author publications in total articles, %C country collaboration ratio, the 
percentage of collaborative articles in total articles for each country
Country/territory TP TPR (%) SPR (%) CPR (%) FAR (%) RPR (%) % C
USA 1995 1 (25.61) 1 (26.69) 1 (23.43) 1 (26.15) 1 (26.47) 29.32
Japan 802 2 (10.30) 2 (12.91) 6 (4.92) 2 (11.59) 2 (11.62) 15.34
Italy 663 3 (8.51) 3 (8.38) 2 (9.09) 3 (8.52) 3 (8.46) 34.24
China (mainland) 549 4 (7.05) 4 (7.48) 5 (6.20) 4 (7.54) 4 (7.51) 28.23
Germany 326 5 (4.16) 9 (2.89) 4 (6.93) 7 (3.61) 7 (3.61) 53.07
UK 324 6 (4.11) 10 (2.68) 3 (7.29) 9 (3.25) 10 (3.12) 56.17
France 313 7 (4.02) 6 (3.95) 8 (4.32) 6 (3.82) 6 (3.85) 34.50
Turkey 253 8 (3.25) 5 (4.46) 23 (0.68) 5 (3.83) 5 (3.83) 6.72
South Korea 245 9 (3.15) 7 (3.50) 12 (2.40) 8 (3.34) 8 (3.34) 24.49
Spain 239 10 (3.07) 8 (3.06) 10 (3.08) 10 (3.20) 9 (3.18) 32.22
Australia 223 11 (2.86) 13 (1.98) 7 (4.72) 11 (2.49) 11 (2.45) 52.91
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It is worth mentioning that China (mainland) topped 
Italy in 2010, and then, leapt over Japan in 2012 to be the 
second place. Moreover, some East Asian countries/terri-
tories such as Japan, China (mainland), South Korea, and 
Taiwan occupied a more and more important place in 
the NAFLD research. The rapid increase of publications 
might be closely related to the ever-growing incidence 
rate of NAFLD in Asia in recent years, the advance of sci-
entific research, and the growth of economic power that 
enabled these countries/territories to put more effort in 
the research and control of NAFLD (Farrell et al. 2013).
Keywords used in bibliometrics could trace the direc-
tion and breakthrough of NAFLD research. The fre-
quency analysis of keywords related to NAFLD indicated 
Fig. 2 Comparison of the NAFLD publication growth trends of top seven countries
Table 3 Top 10 most productive institutes of articles during 1986–2013
TP the number of total publications, SP the number of single institute publications, CP inter-institutionally collaborative publications, FA first author publications, RP 
corresponding author publications, R rank, %C the percentage of collaborative articles in total articles for each institute
Institute R (TP) R (SP) R (CP) R (FA) R (RP) % C
University Calif San Diego, USA 1 (95) 13 (16) 1 (79) 1 (56) 1 (50) 83.16
Mayo Clin, USA 2 (80) 1 (26) 10 (54) 2 (53) 2 (49) 67.50
Johns Hopkins University,USA 3 (73) 4 (20) 12 (53) 14 (33) 19 (26) 72.60
University Turin, Italy 4 (72) 122 (4) 2 (68) 60 (16) 47 (17) 94.44
Duke University,USA 5 (71) 21 (13) 4 (58) 4 (42) 3 (42) 81.69
Washington University,USA 6 (70) 13(16) 10 (54) 9 (37) 7 (35) 77.14
University Milan, Italy 7 (69) 31 (11) 4 (58) 6 (38) 12 (30) 84.06
University Sydney, Australia 8 (67) 31 (11) 6 (56) 10 (36) 16 (27) 83.58
University Washington, USA 9 (65) 44 (9) 6 (56) 81 (14) 70 (14) 86.15
University Calif San Francisco, USA 9 (65) 44 (9) 6 (56) 18 (30) 16 (27) 86.15
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that metabolic syndrome (MS) and its combination of 
symptoms (obesity, insulin resistance, oxidative stress, 
adiponectin, diabetes, etc.) were closely involved in the 
pathogenesis of this disease. Other topics discussed were 
histological characteristics and progression of NAFLD 
in respect that the diagnosis of NAFLD depend on liver 
biopsy (LaBrecque et  al. 2014), which remains the gold 
standard for the diagnosis of NASH (Fan and Farrell 2009).
In all types of publications, meeting abstracts and 
reviews account for more than one third of the publica-
tions, which are relatively high in proportion. Three rea-
sons might explain the low proportion of articles in all 
NAFLD publications. Firstly, the still uncertain pathogen-
esis of NAFLD might hinder the people from researching 
in this filed (Wu et  al. 2011). Secondly, no suitable ani-
mal models replicating the full spectrum of the disease 
in humans might limit the basic research in this field. No 
uniformed diagnosis guidelines and no established ther-
apy, especially no adequate prospective, double-blind, 
controlled trials to provide the data necessary to create 
an evidence-based clinical guideline (LaBrecque et  al. 
2014), might be the third reason for the high proportion 
of meeting abstracts and reviews.
Incidence and prevalence of FAFLD
The obviously rapid growth of the articles in recent years 
might reflect the accelerating incidence of NAFLD. Con-
trary to the prevalence of other chronic liver diseases 
which remained stable or even decreased, the preva-
lence of NAFLD has doubled during last two decades. 
NAFLD and NASH, the number one culprit of liver dis-
ease in western countries, play a similar important role 
in the Middle East, Far East, Africa, the Caribbean, and 
Latin America more recently (LaBrecque et  al. 2014). 
Table 4 The information of top 10 most frequently cited articles
Name of articles Journal First author/institute Year Times cited
Design and validation of a histological 
scoring system for nonalcoholic fatty liver 
disease
Hepatology Kleiner, DE/National Academy of Sciences, 
USA
2005 1575
Nonalcoholic steatohepatitis: a proposal 
for grading and staging the histological 
lesions
American Journal of Gastroenterology Brunt, EM/Saint Louis University, USA 1999 1391
Prevalence of hepatic steatosis in an urban 
population in the United States: impact 
of ethnicity
Hepatology Browning, JD/Donald W. Reynolds Cardio‑
vascular Clinical Research Center, USA
2004 1029
Nonalcoholic fatty liver, steatohepatitis, and 
the metabolic syndrome
Hepatology Marchesini, G/Università di Bologna, Bolo‑
gna, Italy
2003 970
Nonalcoholic fatty liver disease—a feature 
of the metabolic syndrome
Diabetes Marchesini, G/Università di Bologna, Bolo‑
gna, Italy
2001 914
The natural‑history of nonalcoholic 
steatohepatitis—a follow‑up‑study of 42 
patients for up to 21 years
Hepatology POWELL, EE/University of Queensland and 
Department of Pathology, Australia
1990 813
The natural history of nonalcoholic fatty 
liver disease: a population‑based cohort 
study
Gastroenterology Adams, LA/Mayo Clin, CollMed, USA 2005 776
Independent predictors of liver fibrosis in 
patients with nonalcoholic steatohepatitis
Hepatology Angulo, P/Mayo Clinic and Foundation, USA 1999 731
Association of nonalcoholic fatty liver 
disease with insulin resistance
American Journal of Medicine Marchesini, G/Università di Bologna, Bolo‑
gna, Italy
1999 677
Expanding the natural history from crypto‑
genic cirrhosis to of nonalcoholic steato‑
hepatitis: Hepatocellular carcinoma
Gastroenterology Bugianesi, E/University of Turin, Italy 2002 624
Table 5 Eleven most frequent key words during  1986–
2013 (frequency >100)
Rank Keyword Frequency (%)
1 Hepatic steatosis 580 (3.2)
2 Obesity 579 (3.2)
3 Insulin resistance 488 (2.7)
4 Metabolic syndrome 422 (2.3)
5 Liver fibrosis 368 (2.0)
6 Oxidative stress 269 (1.5)
7 Inflammation 128 (1.0)
8 Hepatitis C virus (HCV) 145 (0.8)
9 Adiponectin 138 (0.8)
10 Hepatocellular carcinoma 133 (0.7)
11 Diabetes 133 (0.7)
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The reported prevalence of NAFLD also varies widely 
depending on the definition used and the population 
studied (Williams et al. 2011; Lee et al. 2007; Vernon et al. 
2011; Browning et al. 2004; Lazo et al. 2013; Fleischman 
et  al. 2014). The worldwide prevalence of NAFLD has 
been estimated at 20–30 % (Lopez-Velazquez et al. 2014), 
and 2–3  % of adults have NASH (Neuschwander-Tetri 
2005). In western countries, NAFLD prevalence is up to 
90  % in morbidly obese individuals and NASH is rising 
to 37  % of the morbidly obese (Bedogni et  al. 2005). In 
Asia, the prevalence of NAFLD is reported to be 12–24 % 
(Fan et al. 2007). In China, the prevalence of NAFLD was 
about 15 % in adults in Shanghai, Guangzhou and Hong 
Kong (Fan et  al. 2011). In parallel with the epidemic of 
obesity and metabolic syndrome worldwide, the preva-
lence of NAFLD in Asian countries has increased rapidly 
with a trend to younger patients during the last two dec-
ades (Fan et al. 2007). NAFLD rapidly becomes the most 
common form of chronic liver disease in the pediatric 
population (Lindback et al. 2010).
Potential pathogenesis of NAFLD
The research hotspots extracted from bibliometrics 
information of NAFLD reflect the potential pathogenesis 
of the disease. The analysis of the frequency of keywords 
related with NAFLD indicated that metabolic syndrome 
(MS) and its combination of symptoms such as obesity, 
insulin resistance and diabetes as well as oxidative stress 
and dyslipoproteinemia were closely involved in the 
pathogenesis of this disease. Indeed, although pathogene-
sis of NAFLD remains not fully understood, it is generally 
attributed to the occurrence of insulin resistance, lipid 
metabolism dysfunction, oxidative stress, inflammation, 
and necro-apoptosis, which is consistent with bibliomet-
rics analysis results (Xiao et  al. 2013; Vuppalanchi and 
Chalasani 2009; Rector et al. 2008).
NAFLD/NASH is increasingly regarded as a hepatic 
manifestation of metabolic syndrome, and the severity of 
NAFLD seems to increase in parallel with other features 
of metabolic syndrome (Boppidi and Daram 2008; Liu 
et al. 2010; Marchesini et al. 2003). Thus, it is evident that 
pathogenesis focusing on metabolic syndrome has been 
the prevalent direction of researches. However, not all 
patients with these conditions have NAFLD/NASH, and 
not all patients with NAFLD/NASH suffer from one of 
these conditions (LaBrecque et al. 2014).
Animal model of NAFLD
No suitable animal models replicating the full spectrum 
of the disease in humans might hinder the basic research 
in this field. Animal models that simulate certain fea-
tures of the human disease have provided insights into 
possible pathological mechanisms contributing to its 
development. Animal models used to study the patho-
genesis of NAFLD are generally divided into genetically 
altered, diet induced and combination types (Takahashi 
et  al. 2012; Fan and Qiao 2009; Kanuri and Bergheim 
2013). Genetic models of NAFLD include the animals 
with deficiency in leptin signaling, hepatic lipogenesis, 
β-oxidation, NF-κB and TNF signaling, and cholesterol 
signaling etc. (Anstee and Goldin 2006; Kanuri and 
Bergheim 2013; Nagarajan et al. 2012). Nutritional mod-
els of NAFLD include methionine- and choline-deficient 
model, high fat diet model, atherogenic diet model, fruc-
tose model and overnutrition model etc. (Jeong et  al. 
2005; Spruss et al. 2009; Tipoe et al. 2009). Because of the 
occurrence and progression of NAFLD/NASH in human 
being a long period of several decades and its ethical 
limitations, animal models of NAFLD/NASH give crucial 
information, not only in elucidating the pathogenesis of 
NAFLD/NASH but also in examining therapeutic effects 
of various agents (Takahashi et al. 2012). An ideal model 
of NAFLD/NASH should correctly reflect both hepatic 
histopathology and pathophysiology of human NAFLD/
NASH, which will boost the research on this disease.
Treatment progress for NAFLD
Shortage of uniformed diagnosis guidelines and no estab-
lished therapy might also hinder the research in this 
field. It is found that mortality increased only in NASH 
patients but not in patients with common liver steatosis 
after long-term follow-up of patients with NAFLD. So 
only the patients with NASH should be considered to 
receive medical treatment, particularly those who present 
evidence of fibrosis (Machado and Cortez-Pinto 2014). 
The primary goal of NAFLD therapy recommended is to 
prevent the existing comorbidities such as metabolic dis-
orders, cardiovascular or cerebrovascular events, while 
the reversal of hepatic steatosis is the secondary target 
for NAFLD treatment (Basaranoglu and Ormeci 2014; 
Chalasani et  al. 2012; Ekstedt et  al. 2006). Additionally, 
prevention and treatment of NASH, control the progres-
sion of liver disease, and reducing the occurrence of liver 
cirrhosis should also be considered (Machado and Cor-
tez-Pinto 2014).
Lifestyle intervention including weight reduction, 
dietary modification and physical exercise is critical 
in any attempt to reverse the course of NAFLD/NASH 
(Chalasani et al. 2012; LaBrecque et al. 2014). Lifestyle 
modification with diet and exercise is the base of phar-
macological treatment (Agrawal and Duseja 2012). For 
pharmaceutical therapies, a wide range of drugs, includ-
ing antioxidants, insulin sensitizers, lipid lowering 
agents, and rennin-angiotensin system blockers, have 
been applied in clinical trials (Gossard and Lindor 2011; 
Della et  al. 2011; Xiao et  al. 2013). In the Pioglitazone 
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or Vitamin E for NASH Study (PIVENS), investigators 
compared pioglitazone or vitamin E treatments to pla-
cebo. This largest placebo-controlled, randomized clini-
cal trial of therapies ever conducted for NASH provides 
key evidence to support that vitamin E and pioglitazone 
could help certain patients with NASH (Sanyal et  al. 
2010). NAFLD or NASH per se is not an indication for 
bariatric surgery, but there is ample evidence to show 
that sustained weight loss associated with bariatric sur-
gery can improve and even reverse changes of NAFLD 
and NASH (Hafeez and Ahmed 2013; LaBrecque 
et  al. 2014). Liver transplantation could be considered 
for patients with NASH complicated by liver failure, 
decompensated cirrhosis and hepatocellular carcinoma 
(Fan et al. 2011). Herbal treatment is likely to offer cer-
tain health benefits without obvious adverse effects in 
NAFLD therapy in the past decades (Xiao et  al. 2013). 
However, detailed mechanistic researches and long 
term clinical evaluations for Chinese medicine treat-
ment of NAFLD are needed for their future applications 
(Shi et al. 2012; Xiao et al. 2013).
Limitations
In order to ensure a high quality bibliometric analysis, we 
only recruited papers published in SCI-Expanded jour-
nals, which has to pay a price that a considerable amount 
of papers published in non-SCI journals. Especially, the 
vast amount of herbal treatment literature is published in 
Chinese. To compensate this pitfall, another study aiming 
to systemically review the non-SCI papers is needed to 
make a thorough review on papers related with NAFLD 
from bibliometric point of view.
Conclusions
Bibliometric results suggest that the obviously rapid 
growth of the articles in recent years appears to be asso-
ciated with the accelerating incidence of NAFLD and 
its cofactors such as metabolic syndrome. Among the 
research hotspots of NAFLD, insulin resistance, a com-
mon factor in the metabolic syndrome, might play a 
major role in the pathogenesis research of NAFLD. In 
addition, epidemiology focusing on comparing different 
regions and population is attracting ever-growing atten-
tion. Meantime, pathology plays an important role in 
NAFLD research. With the research on NAFLD boom-
ing, a more effective way to prevent or control the global 
prevalence of NAFLD will be expected in the near future.
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